Content about Injection

March 27, 2013
FDA approves injectable antihistamine using BD Simplist

The Food and Drug Administration has approved a drug administered through a new line of injection devices made by BD, the company said Wednesday.

FRANKLIN LAKES, N.J. — The Food and Drug Administration has approved a drug administered through a new line of injection devices made by BD, the company said Wednesday.

BD announced the approval of diphenhydramine hydrochloride injection, an antihistamine, packaged in its recently launched Simplist pre-filled injectables, which are made by subsidiary BD Rx and designed to improve patient care and safety by decreasing the number of steps in the traditional vial and syringe injection sequence and thus reduce the potential risk of medication errors.

December 27, 2012
Walgreens Infusion Services selected as a contracted provider of just-approved long-term treatment for SBS

Walgreens Infusion Services has been selected as a contracted provider of a new injectable medication that helps patients with short bowel syndrome.

DEERFIELD, Ill. — Walgreens Infusion Services has been selected as a contracted provider of a new injectable medication that helps patients with short bowel syndrome get more — or all — of their nutrients orally, reducing their dependence on intravenous parenteral nutrition, the division announced Wednesday.

October 12, 2012
BD introduces disposable injection pen

Medical supply company BD has introduced a disposable injection pen that it said was designed for drugs requiring frequent, low-volume injections or variable dosing.

FRANKLIN LAKES, N.J. — Medical supply company BD has introduced a disposable injection pen that it said was designed for drugs requiring frequent, low-volume injections or variable dosing.

The company's BD Medical division announced the introduction of the Vystra, which it will showcase at the 2012 Parenteral Drug Association meeting in Las Vegas.

The company said the pen is designed for ease of use, comfort and reliability, including design features like multi-dosing, simple dose dialing and correction with audible clicks and large and clear dose markings.

September 26, 2012
BD introduces new, thinner needle for diabetes patients

BD has introduced a needle that it said was designed to enhance adherence and comfort among patients with diabetes.

FRANKLIN LAKES, N.J. — BD has introduced a needle that it said was designed to enhance adherence and comfort among patients with diabetes.

January 24, 2012
FDA approves new administration method for Takeda cancer drug

The Food and Drug Administration has approved a new means of administering a cancer drug made by Takeda, the drug maker said.

CAMBRIDGE, Mass. — The Food and Drug Administration has approved a new means of administering a cancer drug made by Takeda, the drug maker said.

The FDA approved injection under the skin of Velcade (bortezomib) for multiple myeloma and mantle-cell lymphoma, also known as subcutaneous injection.

Takeda said the approval was based on results of a phase-3 trial conducted on 222 patients who had not received the drug before that showed subcutaneous injection worked as well as intravenous injection.

September 6, 2011
Armada Health Care, Hemispherx sign sales, distribution agreement for Alferon N Injection

Hemispherx Biopharma and Armada Health Care have entered a sales and marketing agreement for a drug designed to treat genital warts.

PHILADELPHIA — Hemispherx Biopharma and Armada Health Care have entered a sales and marketing agreement for a drug designed to treat genital warts.

The two companies announced Tuesday an agreement under which Hemispherx will manufacture and supply Alferon N injection (interferon alfa-n3 [human leukocyte derived]) to physicians and patients through Armada's national specialty pharmacy network. Specialty distributor BioRidge Pharma will warehouse, ship and distribute the drug, the companies said.

August 1, 2011
FDA approves subcutaneous formulation of Orencia

The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb for injection under the skin to treat rheumatoid arthritis, Bristol said Friday.

PRINCETON, N.J. — The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb for injection under the skin to treat rheumatoid arthritis, Bristol said Friday.

The New York-based drug maker said the approval of Orencia (abatacept) for subcutaneous injection in patients with moderate to severe RA made it the first biotech drug for RA available in self-injectable and intravenous infusion formulations.

December 7, 2010
Bristol-Myers Squibb seeks additional approval for Orencia

The Food and Drug Administration has accepted for review a supplemental approval application for an arthritis drug made by Bristol-Myers Squibb, the drug maker said Monday.

PRINCETON, N.J. — The Food and Drug Administration has accepted for review a supplemental approval application for an arthritis drug made by Bristol-Myers Squibb, the drug maker said Monday.

Bristol is seeking approval for Orencia (abatacept) injected into the skin as a treatment for adults with moderate to severe rheumatoid arthritis. The drug already is approved for intravenous injection.

September 12, 2010
FDA accepts approval application for Fluzone Intradermal

The Food and Drug Administration has accepted a regulatory approval application for a flu vaccine...

SWIFTWATER, Pa. The Food and Drug Administration has accepted a regulatory approval application for a flu vaccine administered in the skin.

 

Sanofi Pasteur, the vaccines arm of French drug maker Sanofi-Aventis, announced Monday that the FDA had accepted its application for Fluzone Intradermal (influenza virus vaccine). The company expects the FDA to take action on the vaccine in the first half of next year.